seasonal influenza vaccine + pneumococcal vaccine

This drug entry refers to the co-administration of a seasonal influenza vaccine and a 13-valent pneumococcal conjugate vaccine (specifically Prevenar 13) as evaluated in the VACCIMIL clinical research program sponsored by Region Skane. The seasonal influenza vaccine is typically an inactivated vaccine designed to provide active immunity against circulating influenza A and B strains by targeting viral hemagglutinin. The pneumococcal component, Prevenar 13, is a conjugate vaccine containing capsular polysaccharides from 13 serotypes of Streptococcus pneumoniae, each covalently linked to a non-toxic CRM197 carrier protein to enhance T-cell dependent immune responses. This combination is primarily studied to assess its safety, immunogenicity, and clinical efficacy in patients with inflammatory rheumatic diseases (IRD) who are receiving immunosuppressive or anti-inflammatory therapies.

Brand names

Prevenar 13Prevenar13Prevenar-13

Other names

seasonal influenza vaccine-Region Skane-pneumococcal infection13-valent pneumococcal conjugate vaccineseasonal influenza vaccine